The quest for a T cell-based immune correlate of protection against HIV: A story of trials and errors

Nature Reviews Immunology

Volumn 11, Issue 1, 2011, Pages 65-70

  Koup, Richard A ^a   Graham, Barney S ^a   Douek, Daniel C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; INFECTION PREVENTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV-1; HIV-2; HUMANS; MALE; PRIMATES; T-LYMPHOCYTES;

EID: 78650598765     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2890     Document Type: Review

References (70)

1. Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
2. Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665 (2005).
3. Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
4. Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
5. Pantaleo, G. & Koup, R. A. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nature Med. 10, 806-810 (2004).
6. Plotkin, S. A. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47, 401-409 (2008).
7. Fowke, K. R. et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348, 1347-1351 (1996).
8. Baker, B. M., Block, B. L., Rothchild, A. C. & Walker, B. D. Elite control of HIV infection: implications for vaccine design. Expert Opin. Biol. Ther. 9, 55-69 (2009).
9. Leligdowicz, A. & Rowland-Jones, S. Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection. Expert Rev. Vaccines 7, 319-331 (2008).
10. Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
11. McMichael, A. J., Borrow, P., Tomaras, G. D., Goonetilleke, N. & Haynes, B. F. The immune response during acute HIV-1 infection: clues for vaccine development. Nature Rev. Immunol. 10, 11-23 (2010).
12. Price, H. et al. A TRIM5α exon 2 polymorphism is associated with protection from HIV-1 infection in the Pumwani sex worker cohort. AIDS 24, 1813-1821 (2010).
13. Rowland-Jones, S. L. et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102, 1758-1765 (1998).
14. + T cell responses associated with control of viremia. Science 278, 1447-1450 (1997).
15. + T-cell responses to the Gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J. Virol. 76, 2298-2305 (2002).
16. Ogg, G. S. et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279, 2103-2106 (1998).
17. + T memory phenotypes in subtype C HIV-1 infection with viral set point. J. Immunol. 182, 4751-4761 (2009).
18. + T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2, e321 (2007).
19. + T cells with an effector phenotype and control of viral replication. Lancet 363, 863-866 (2004).
20. Day, C. L. et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J. Virol. 81, 434-438 (2007).
21. Hersperger, A. R. et al. Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 6, e1000917 (2010).
22. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29, 1009-1021 (2008).
23. Yang, O. O. et al. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes. J. Virol. 70, 5799-5806 (1996).
24. + cells correlates with the clinical state of HIV-infected individuals. Proc. Natl Acad. Sci. USA 93, 13125-13130 (1996).
25. Spentzou, A. et al. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 201, 720-729 (2010).
26. + cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J. Virol. 71, 3120-3128 (1997).
27. + T cells. Blood 107, 4781-4789 (2006).
28. Geldmacher, C. et al. Minor viral and host genetic polymorphisms can dramatically impact the biologic outcome of an epitope-specific CD8 T-cell response. Blood 11 4, 1553-1562 (2009).
29. Simons, B. C. et al. Despite biased TRBV gene usage against a dominant HLA B57-restricted epitope, TCR diversity can provide recognition of circulating epitope variants. J. Immunol. 181, 5137-5146 (2008).
30. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350-354 (2006).
31. + T cell survival in HIV infection. J. Exp. Med. 203, 2281-2292 (2006).
32. + T cells leads to reversible immune dysfunction. Nature Med. 12, 1198-1202 (2006).
33. + T-cell responses to different HIV proteins have discordant associations with viral load. Nature Med. 13, 46-53 (2007).
34. Rolland, M. et al. Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads. PLoS ONE 3, e1424 (2008).
35. Zuniga, R. et al. Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J. Virol. 80, 3122-3125 (2006).
36. Gao, X. et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344, 1668-1675 (2001).
37. Hendel, H. et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J. Immunol. 162, 6942-6946 (1999).
38. Kaslow, R. A. et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nature Med. 2, 405-411 (1996).
39. Migueles, S. A. et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl Acad. Sci. USA 97, 2709-2714 (2000).
40. Goulder, P. J. et al. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res. Hum. Retroviruses 12, 1691-1698 (1996).
41. + T cell responses strongly associated with delayed disease progression cross-recognize epitope variants efficiently. J. Immunol. 176, 6130-6146 (2006).
42. Martinez-Picado, J. et al. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80, 3617-3623 (2006).
43. Schneidewind, A. et al. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 81, 12382-12393 (2007).
44. Betts, M. R. et al. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc. Natl Acad. Sci. USA 102, 4512-4517 (2005).
45. + T cells. J. Virol. 83, 7641-7648 (2009).
46. Goulder, P. J. et al. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193, 181-194 (2001).
47. Goonetilleke, N. et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206, 1253-1272 (2009).
48. Leslie, A. J. et al. HIV evolution: CTL escape mutation and reversion after transmission. Nature Med. 10, 282-289 (2004).
49. Feeney, M. E. et al. HIV-1 viral escape in infancy followed by emergence of a variant-specific CTL response. J. Immunol. 174, 7524-7530 (2005).
50. Goepfert, P. A. et al. Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. J. Exp. Med. 205, 1009-1017 (2008).
51. Goulder, P. J. et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412, 334-338 (2001).
52. Gray, R. H. et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357, 1149-1153 (2001).
53. Wawer, M. J. et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191, 1403-1409 (2005).
54. Salazar-Gonzalez, J. F . et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/ founder viruses in acute and early HIV-1 infection. J. Exp. Med. 206, 1273-1289 (2009).
55. Keele, B. F. et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206, 1117-1134 (2009).
56. Hudgens, M. G. et al. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J. Infect. Dis. 200, 609-613 (2009).
57. Morgan, C. et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 5, e173 (2008).
58. + T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc. Natl Acad. Sci. USA 101, 12324-12329 (2004).
59. Shedlock, D. J., Silvestri, G. & Weiner, D. B. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nature Rev. Immunol. 9, 717-728 (2009).
60. McElrath, M. J. et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372, 1894-1905 (2008).
61. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
62. Hansen, S. G. et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nature Med. 15, 293-299 (2009).
63. D'Souza, M. P. & Altfeld, M. Measuring HIV-1-specific T cell immunity: how valid are current assays? J. Infect. Dis. 197, 337-339 (2008).
64. Streeck, H., Frahm, N. & Walker, B. D. The role of IFN-γ Elispot assay in HIV vaccine research. Nature Protoc. 4, 461-469 (2009).
65. Janetzki, S., Cox, J. H., Oden, N. & Ferrari, G. Standardization and validation issues of the ELISPOT assay. Methods Mol. Biol. 302, 51-86 (2005).
66. Baeten, J. M. et al. Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials. J. Acquir. Immune Defic. Syndr. 24, 458-464 (2000).
67. Kaul, R. et al. Reduced HIV risk-taking and low HIV incidence after enrollment and risk-reduction counseling in a sexually transmitted disease prevention trial in Nairobi, Kenya. J. Acquir. Immune Defic. Syndr. 30, 69-72 (2002).
68. Van Loggerenberg, F. et al. Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS ONE 3, e1954 (2008).
69. Qin, L., Gilbert, P. B., Corey, L., McElrath, M. J. & Self, S. G. A framework for assessing immunological correlates of protection in vaccine trials. J. Infect. Dis. 196, 1304-1312 (2007).
70. The Council of the Global HIV Vaccine Enterprise et al. The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise. Nature Med. 16, 981-989 (2010).